Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 93.54% shareholder participation, with 90,399,636.29 shares voted or represented by proxy.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 93.54% shareholder participation, with 90,399,636.29 shares voted or represented by proxy
- All eight director nominees elected through 2027, with opposition ranging from 388,586.65 to 4,517,221.65 votes
- Say-on-pay approved, 82,156,320.53 votes for versus 4,769,025.65 against
- Annual say-on-pay frequency overwhelmingly selected, with 86,918,084.18 votes for one-year intervals
- 2026 Equity Incentive Plan approved narrowly, 58,579,810 votes for versus 27,570,443.18 against
- PwC auditor appointment and audit committee authority over remuneration approved with 90,371,967.64 and 90,370,029.64 votes, respectively
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.